Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2018
At a glance
- Drugs Ravulizumab (Primary)
- Indications Haemolytic uraemic syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Alexion Pharmaceuticals
- 08 Feb 2018 According to an Alexion Pharmaceuticals media release, data from this study is expected in the fourth quarter of 2018. And enrollment is expected to be complete in the second quarter of 2018
- 30 Jan 2018 Planned End Date changed from 1 Dec 2019 to 1 Nov 2020.
- 30 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.